Biomarkers of antimony resistance: Need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani

Parasitology Research

Volumn 111, Issue 1, 2012, Pages 223-230

  Kumar, Dhiraj ^a,c   Singh, Ruchi ^b   Bhandari, Vasundhra ^a   Kulshrestha, Arpita ^a   Negi, Narendra Singh ^a   Salotra, Poonam ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b NATIONAL INSTITUTE OF MALARIA RESEARCH   (India)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY GLUCONATE; AQUAPORIN 1; BIOLOGICAL MARKER; GLUTAMATE CYSTEINE LIGASE; HISTONE H1; HISTONE H2A; HISTONE H4; MITOGEN ACTIVATED PROTEIN KINASE 1;

AQP1 GENE; ARTICLE; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG SENSITIVITY; GAMMA GCS GENE; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; H1 GENE; H2A GENE; H4 GENE; HSP83 GENE; LEISHMANIA DONOVANI; MAPK1 GENE; MOSAICISM; MRPA GENE; NONHUMAN; PARASITE IDENTIFICATION; PARASITE ISOLATION; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; VISCERAL LEISHMANIASIS;

ANTIMONY; ANTIPROTOZOAL AGENTS; BIOLOGICAL MARKERS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; HUMANS; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PROTOZOAN PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION;

LEISHMANIA DONOVANI;

EID: 84862771688     PISSN: 09320113     EISSN: 14321955     Source Type: Journal    
DOI: 10.1007/s00436-012-2823-z     Document Type: Article

References (31)

1. V Adaui K Schnorbusch M Zimic A Gutiérrez S Decuypere M Vanaerschot S DE Doncker I Maes A Llanos-Cuentas F Chappuis J Arévalo JC Dujardin 2011 Comparison of gene expression patterns among Leishmania braziliensis clinical isolates showing a different in vitro susceptibility to pentavalent antimony Parasitology 138 183 193 20678296 10.1017/S0031182010001095 1:CAS:528:DC%2BC3MXpvFSltQ%3D%3D
2. MD Boer RN Davidson 2006 Treatment options for visceral leishmaniasis Expert Rev Anti Infect Ther 4 187 197 10.1586/14787210.4.2.187
3. SL Croft S Sundar AH Fairlamb 2006 Drug resistance in leishmaniasis Clin Microbiol Rev 19 111 126 16418526 10.1128/CMR.19.1.111-126.2006 1:CAS:528:DC%2BD28XhsFGjtbk%3D
4. S Decuypere S Rijal V Yardley S De Doncker T Laurent B Khanal F Chappuis JC Dujardin 2005 Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal Antimicrob Agents Chemother 49 4616 4621 16251303 10.1128/AAC.49.11.4616-4621.2005 1:CAS:528:DC%2BD2MXht1Siu7zK
5. S Decuypere M Vanaerschot S Rijal V Yardley L Maes S de Doncker F Chappuis JC Dujardin 2008 Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation Parasitology 135 183 194 17931458 10.1017/S0031182007003782 1:CAS:528: DC%2BD1cXhtVGitbk%3D
6. K El Fadili N Messier P Leprohon G Roy C Guimond N Trudel NG Saravia B Papadopoulou D Légaré M Ouellette 2005 Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes Antimicrob Agents Chemother 49 1988 1993 15855523 10.1128/AAC.49.5.1988-1993.2005
7. B Gourbal N Sonuc H Bhattacharjee D Legare S Sundar M Ouellette BP Rosen R Mukhopadhyay 2004 Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin J Biol Chem 279 31010 31017 15138256 10.1074/jbc. M403959200 1:CAS:528:DC%2BD2cXlslOktbw%3D
8. A Haimeur C Brochu P Genest B Papadopoulou M Ouellette 2000 Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae Mol Biochem Parasitol 108 131 135 10802326 10.1016/S0166-6851(00)00187-0 1:CAS:528:DC%2BD3cXjtVCis7o%3D
9. D Kumar A Kulshrestha R Singh P Salotra 2009 In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity Antimicrob Agents Chemother 53 835 838 19015344 10.1128/AAC.01233-08 1:CAS:528:DC%2BD1MXhslemsLg%3D
10. A Kumar B Sisodia P Misra S Sundar AK Shasany A Dube 2010 Proteome mapping of overexpressed membrane-enriched and cytosolic proteins in sodium antimony gluconate (SAG) resistant clinical isolate of Leishmania donovani Br J Clin Pharmacol 70 609 617 20840452 10.1111/j.1365-2125.2010.03716.x 1:CAS:528:DC%2BC3cXhtlCrurrP
11. R Lira S Sundar A Makharia R Kenney A Gam E Saraiva D Sacks 1999 Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani J Infect Dis 180 564 567 10395884 10.1086/314896 1:CAS:528:DyaK1MXlt1ygtrc%3D
12. M Maharjan S Singh M Chatterjee R Madhubala 2008 Role of aquaglyceroporin (AQP1) gene and drug uptake in antimony-resistant clinical isolates of Leishmania donovani Am J Trop Med Hyg 79 69 75 18606765 1:CAS:528: DC%2BD1cXptlWqs7Y%3D
13. MK Mittal S Rai R Ashutosh S Gupta S Sundar N Goyal 2007 Characterization of natural antimony resistance in Leishmania donovani isolates Am J Trop Med Hyg 76 681 688 17426170 1:CAS:528:DC%2BD2sXltFSqtL8%3D
14. A Mukherjee PK Padmanabhan SM Singh G Roy I Girard M Chatterjee M Ouellette R Madhubala 2007 Role of ABC transporter MRPA, gamma-glutamylcysteine synthetase and ornithine decarboxylase in natural antimony-resistant isolates of Leishmania donovani J Antimicrob Chemother 59 204 211 17213267 10.1093/jac/dkl494 1:CAS:528:DC%2BD2sXjt1ChtLc%3D
15. A Mukherjee G Roy C Guimond M Ouellette 2009 The gamma-glutamylcysteine synthetase gene of Leishmania is essential and involved in response to oxidants Mol Microbiol 74 914 927 19818018 10.1111/j.1365-2958.2009.06907.x 1:CAS:528:DC%2BD1MXhsFCit7%2FJ
16. M Ouellette J Drummelsmith B Papadopoulou 2004 Leishmaniasis: drugs in the clinic, resistance and new developments Drug Resistant Update 7 257 266 10.1016/j.drup.2004.07.002 1:CAS:528:DC%2BD2cXpsVOlu7c%3D
17. FJ Pérez-Victoria MP Sánchez-Cañete K Seifert SL Croft S Sundar S Castanys F Gamarro 2006 Mechanisms of experimental resistance of Leishmania to miltefosine: implications for clinical use Drug Resist Updat 9 26 39 16814199 10.1016/j.drup.2006.04.001
18. R Rojas L Valderrama M Valderrama MX Varona M Ouellette NG Saravia 2006 Resistance to antimony and treatment failure in human Leishmania Viannia infection J Infect Dis 193 1375 1383 16619185 10.1086/503371 1:CAS:528:DC%2BD28Xlt1ejtbk%3D
19. N Singh RT Singh S Sundar 2003 Novel mechanism of drug resistance in kala azar field isolates J Infect Dis 188 600 607 12898450 10.1086/377133 1:CAS:528:DC%2BD3sXnsVSltL8%3D
20. R Singh D Kumar V Ramesh NS Negi S Singh P Salotra 2006 Visceral leishmaniasis, or kala azar (KA): high incidence of refractoriness to antimony is contributed by anthroponotic transmission via post-KA dermal leishmaniasis J Infect Dis 194 302 306 16826477 10.1086/505079 1:CAS:528:DC%2BD28Xot1aks78%3D
21. R Singh D Kumar R Duncan HL Nakhasi P Salotra 2010 Over expression of histone H2A modulates drug susceptibility in L. donovani parasites Int J Antimicrob Agents 36 50 57 20427152 10.1016/j.ijantimicag.2010.03.012 1:CAS:528:DC%2BC3cXmsVGrtr8%3D
22. G Sreenivas BV Raju R Singh A Selvapandiyan R Duncan D Sarkar HL Nakhasi P Salotra 2004 DNA polymorphism assay distinguishes isolates of Leishmania donovani that cause kala-azar from those that cause post-kala-azar dermal leishmaniasis in humans J Clin Microbiol 42 1739 1741 15071036 10.1128/JCM.42.4.1739-1741.2004 1:CAS:528:DC%2BD2cXjvFyltbw%3D
23. G Sreenivas R Singh A Selvapandiyan NS Negi HL Nakhasi P Salotra 2004 Arbitrary-primed PCR for genomic fingerprinting and identification of differentially regulated genes in Indian isolates of Leishmania donovani Exp Parasitol 106 110 118 15172218 10.1016/j.exppara.2004.03.011 1:CAS:528:DC%2BD2cXksVansL0%3D
24. S Sundar 2001 Drug resistance in Indian visceral leishmaniasis Trop Med Int Health 6 849 854 11703838 10.1046/j.1365-3156.2001.00778.x 1:STN:280:DC%2BD3MnltFOqsQ%3D%3D
25. S Sundar DK More MK Singh VP Singh S Sharma A Makharia PC Kumar HW Murray 2000 Failure of pentavalent antimony in visceral leishmaniasis in India: report from the centre of the Indian epidemic Clin Infect Dis 31 1104 1106 11049798 10.1086/318121 1:STN:280:DC%2BD3M7htVagug%3D%3D
26. S Sundar TK Jha CP Thakur M Mishra VR Singh R Buffels 2002 Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study Am J Trop Med Hyg 66 143 146 12135284 1:CAS:528: DC%2BD38XlvFWhs7g%3D
27. R t'Kindt RA Scheltema A Jankevics K Brunker S Rijal JC Dujardin R Breitling DG Watson GH Coombs S Decuypere 2010 Metabolomics to unveil and understand phenotypic diversity between pathogen populations PLoS Negl Trop Dis 4 e904 21152055 10.1371/journal.pntd.0000904
28. DC Torres V Adaui M Ribeiro-Alves GA Romero J Arévalo E Cupolillo JC Dujardin 2010 Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes Infect Genet Evol 10 727 733 20478409 10.1016/j.meegid.2010.05.006 1:CAS:528:DC%2BC3cXotVWlt78%3D
29. B Vergnes B Gourbal I Girard S Sundar J Drummelsmith M Ouellette 2007 A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death Mol Cell Proteomics 6 88 101 17050524 1:CAS:528:DC%2BD2sXnvVyktA%3D%3D
30. M Wiese 2007 Leishmania MAP kinases-familiar proteins in an unusual context Int J Parasitol 37 1053 1062 17548090 10.1016/j.ijpara.2007.04.008 1:CAS:528:DC%2BD2sXnslWgtbY%3D
31. V Yardley N Ortuno A Llanos-Cuentas F Chappuis SD Doncker L Ramirez S Croft J Arevalo V Adaui H Bermudez S Decuypere JC Dujardin 2006 American tegumentary leishmaniasis: is antimonial treatment outcome related to parasite drug susceptibility? J Infect Dis 194 1168 1175 16991093 10.1086/507710